Literature DB >> 8481663

Asparaginase revisited.

R L Capizzi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8481663     DOI: 10.3109/10428199309149127

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  6 in total

1.  Consequences of nonadaptive alterations in cancer.

Authors:  Alexander Kamb
Journal:  Mol Biol Cell       Date:  2003-02-21       Impact factor: 4.138

2.  Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).

Authors:  Joanne Kurtzberg; Barbara Asselin; Mark Bernstein; George R Buchanan; Brad H Pollock; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

Review 3.  Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.

Authors:  Vassilios I Avramis; Eduard H Panosyan
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Treatment of acute lymphoblastic leukaemia : a new era.

Authors:  Effrosyni Apostolidou; Ronan Swords; Yesid Alvarado; Francis J Giles
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  First-line treatment of acute lymphoblastic leukemia with pegasparaginase.

Authors:  Riccardo Masetti; Andrea Pession
Journal:  Biologics       Date:  2009-07-13

Review 6.  Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.

Authors:  Vassilios I Avramis; Prakash Nidhi Tiwari
Journal:  Int J Nanomedicine       Date:  2006
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.